Literature DB >> 31664474

An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?

Ivana Mikačić1,2.   

Abstract

Entities:  

Keywords:  Chronic kidney disease; Eplerenone; Hyperaldosteronism; Spironolactone

Mesh：

Substances：

Year:  2019        PMID： 31664474     DOI： 10.1007/s00228-019-02774-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

Review 2.  Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.

Authors:  Mohammed I Danjuma; Ipshita Mukherjee; Janine Makaronidis; Serge Osula
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 3.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2017-04-28       Impact factor: 29.690

Review 4.  New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.

Authors:  Irene Capelli; Lorenzo Gasperoni; Marco Ruggeri; Gabriele Donati; Olga Baraldi; Giovanni Sorrenti; Maria Turchese Caletti; Valeria Aiello; Giuseppe Cianciolo; Gaetano La Manna
Journal:  J Nephrol       Date:  2019-04-15       Impact factor: 3.902

5.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 6.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.

Authors:  Peter Kolkhof; Lars Bärfacker
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.